Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples (ALS-TDI PEG)
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
研究概览
地位
条件
详细说明
Subjects who are undergoing a percutaneous endoscopic gastrostomy (PEG) tube insertion as part of their standard of care will be asked if a skin and adipose sample may be collected for research during the procedure. After a participant has signed the informed consent, the sub-investigator from the Department of Gastroenterology will collect a skin and adipose sample during the procedure. Individuals with a diagnosis of definite ALS and disease controls (i.e. stroke, head and neck cancer, spinal cord injury, etc.) will be included in this study.
The coded skin and adipose sample will be taken to the Carolinas Neuromuscular/ALS Research Laboratory in the Cannon Research Center for processing. The skin and adipose will be separated from each other and divided into halves. Each half of skin and adipose will be submerged in preservative and either shipped to ALS-TDI or retained at -80°C in the Carolinas Neuromuscular/ALS Research Laboratory. The research staff at the Carolinas Neuromuscular/ALS-MDA Center will be responsible for shipping the sample to the ALS-TDI for either RNA isolation using the Qiagen RNAEasy kit (Qiagen) or for purification of protein. Subsequently, gene expression profiling on Affymetrix Genechips or Mass Spec based proteomics on a Thermo Orbitrap LC-MS/MS instrument will be performed, respectively. The discovery effort (if all participants are working at capacity) should not take more than 12 months.
In addition to the above procedures, a member of the study team will review the medical chart to obtain additional information on the participant's medical and family history. For ALS patients, past ALSFRS-R scores or FVC scores will be provided to the "ALS-TDI Skin and Adipose Biomarker Study" to enhance the usefulness of the information for research.
Samples will not be stored with any patient identifiers. Samples will be retained and continued to be studied as new techniques become available. Data from the study may be published in scientific journals. Publications will not include any patient identifiers.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
North Carolina
-
Charlotte、North Carolina、美国、28207
- Carolinas Neuromuscular/ALS-MDA care Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- for ALS patients, subjects must be diagnosed with definite ALS according to the El Escorial Criteria (EEC)
- all subjects must be diagnosed with a condition requiring PEG (percutaneous endoscopic gastrostomy) tube insertion
- subjects must be older than 18 years of age
Exclusion Criteria:
- children 18 years old and younger
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
subjects with ALS
subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
|
|
subjects without ALS
subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Abundance levels of the known messenger RNA transcriptome of skin and adipose tissue samples (measured by gene expression profiling)
大体时间:After tissue has been collected from study subjects. Data will be analyzed at 1 year.
|
Skin and adipose samples will be collected and processed into total RNA.
Probes will be synthesized from these total RNAs and hybridized to HgU133ver2.0 Affymetrix genechips.
These genechips contain probe sets that measure the abundance levels of the known human transcriptome.
|
After tissue has been collected from study subjects. Data will be analyzed at 1 year.
|
|
Changes in abundance of or post-translational modification of proteins (measured by proteomics)
大体时间:After tissue has been collected from study subjects. Data will be analyzed at year 1 after primary outcome data has been reviewed and analyzed.
|
Skin and adipose samples will be collected for down stream proteomics analysis.
The 14 most abundant proteins will be removed using commercially available depletion columns (Agilent).
Removal of these proteins yields higher resolution and sensitivity in subsequent chromatography steps.
Proteins will be separated by 2 and 3 dimensional liquid chromatography followed by MS/MS based peptide quantitation and sequencing on a Thermo Orbitrap.
|
After tissue has been collected from study subjects. Data will be analyzed at year 1 after primary outcome data has been reviewed and analyzed.
|
合作者和调查者
调查人员
- 首席研究员:Benjamin R Brooks, MD、Carolinas Neuromuscular/ALS-MDA care Center
- 首席研究员:Thomas Pacicco, MD、Gastroenterology
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.